REFERENCES
- Araujo Viel T, Diogo Domingos C, da Silva Monteiro AP, Riggio Lima-Landman MT, Lapa AJ, Souccar C. Evaluation of the antiurolithiatic activity of the extract of Costus spiralis Roscoe in rats. J Ethnopharmacol. 1999;66:193–198.
- Touhami M, Laroubi A, Elhabazi K., Lemon juice has protective activity in a rat urolithiasis model. BMC Urology. 2007;7:18.
- Bayir Y, Halici Z, Keles MS., Helichrysum plicatum DC. subsp. plicatum extract as a preventive agent in experimentally induced urolithiasis model. J Ethnopharmacol. 2011;138:408–414.
- Montjoy CA, Rahman A, Teba L. Ethylene glycol and methanol poisonings: case series and review. W V Med J. 2010;106:17–23.
- Lovric M, Granic P, Cubrilo-Turek M, Lalic Z, Sertic J. Ethylene glycol poisoning. Forensic Sci Int. 2007;170:213–215.
- Wollersen H, Erdmann F, Risse M, Dettmeyer R. Oxalate-crystals in different tissues following intoxication with ethylene glycol: three case reports. Leg Med (Tokyo). 2009;11(Suppl. 1):S488–S490.
- Curtin L, Kraner J, Wine H, Savitt D, Abuelo JG. Complete recovery after massive ethylene glycol ingestion. Arch Intern Med. 1992;152:1311–1313.
- White NC, Litovitz T, Benson BE, Horowitz BZ, Marr-Lyon L, White MK. The impact of bittering agents on pediatric ingestions of antifreeze. Clin Pediatr. 2009;48:913–921.
- Hatchett R. A severe and fatal case of ethylene glycol poisoning. Intensive Crit Care Nurs. 1993;9:183–190.
- Domingos F, Serra A. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant. 2011;26:864–868.
- Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006;8:357–373.
- Carter AJ, Gardiner DG, Burges RA. Natriuretic activity of amlodipine, diltiazem, and nitrendipine in saline-loaded anesthetized dogs. J Cardiovasc Pharmacol. 1988;12(Suppl. 7):S34–S38.
- Sarica K, Inal Y, Erturhan S, Yagci F. The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res. 2006;34:184–189.
- Toblli JE, Ferder L, Angerosa M, Inserra F. Effects of amlodipine on tubulointerstitial lesions in normotensive hyperoxaluric rats. Hypertension. 1999;34:854–858.
- Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens. 2008;21:257–264.
- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223.
- Chobanian AV, Bakris GL, Black HR., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252.
- Sarica K, Erturhan S, Altay B. Effect of verapamil on urinary stone-forming risk factors. Urol Res. 2007;35:23–27.
- Beach MA, Mauro LS. Pharmacologic expulsive treatment of ureteral calculi. Ann Pharmacother. 2006;40:1361–1368.
- Borissova A, Goltz GE, Kavanagh JP, Wilkins TA. Reverse engineering the kidney: modelling calcium oxalate monohydrate crystallization in the nephron. Med Biol Eng Comput. 2010;48:649–659.
- Hussain M, Rizvi SA, Askari H., Management of stone disease: 17 years experience of a stone clinic in a developing country. J Pak Med Assoc. 2009;59:843–846.
- Johns EJ. A study of the renal actions of amlodipine in the normotensive and spontaneously hypertensive rat. Br J Pharmacol. 1988;94:311–318.
- Sorensen MD, Duh QY, Grogan RH, Tran TC, Stoller ML. Urinary parameters as predictors of primary hyperparathyroidism in patients with nephrolithiasis. J Urol. 2012;187:516–521.
- Khan SR, Glenton PA. Experimental induction of calcium oxalate nephrolithiasis in mice. J Urol. 2010;184:1189–1196.
- Spasov AA, Iezhitsa IN, Kharitonova MV, Kravchenko MS. Effects of magnesium salts on the course of experimental calcium-oxalate urolithiasis. Urologiia. 2011;2:23–29.